Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Accrued research, development & commercialization costs by Year
Accrued research, development & commercialization costs ($M) ($M)
Vertex Pharmaceuticals Accrued research, development & commercialization costs: $247M in FY2025, down 9.5% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Accrued Expenses Breakdown).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued research, development & commercialization costs ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 247 | -9.5% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 273 | +2.8% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 265 | +33.5% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 199 | +15.8% | Form 10-K (filed 2024-02-15) ↗ |
| FY2021 | Dec 31, 2021 | 172 | +25.5% | Form 10-K (filed 2023-02-10) ↗ |
| FY2020 | Dec 31, 2020 | 137 | +29.3% | Form 10-K (filed 2022-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 106 | -8.3% | Form 10-K (filed 2021-02-11) ↗ |
| FY2018 | Dec 31, 2018 | 115 | +17.2% | Form 10-K (filed 2020-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 98.4 | +56.7% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 62.8 | +12.7% | Form 10-K (filed 2018-02-15) ↗ |
| FY2015 | Dec 31, 2015 | 55.7 | – | Form 10-K (filed 2017-02-23) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Accrued research, development & commercialization costs ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/accrued-rd-comm
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.